Dr. G explores exosomes—small, cell‑derived vesicles—and how they may accelerate diabetic foot ulcer healing by modulating inflammation, promoting angiogenesis, boosting cell proliferation, and improving matrix remodeling. Strong and consistent animal data show faster closure and better vascularity, and early human trials are beginning.
Yet important hurdles remain: standardization of sources and isolation, scalable GMP manufacturing, long‑term safety monitoring, and regulatory approval. If validated, exosome products could become powerful adjuncts to standard wound care like debridement, offloading, infection control, and vascular optimization.
